IFN-γ Signature Enables the Selection of Neoadjuvant Treatment in Patients With Stage III Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
J Exp Med 2023 May 01;220(5)e20221952, ILM Reijers, D Rao, JM Versluis, AM Menzies, P Dimitriadis, MW Wouters, AJ Spillane, WMC Klop, A Broeks, LJW Bosch, M Lopez-Yurda, WJ van Houdt, RV Rawson, LG Grijpink-Ongering, M Gonzalez, S Cornelissen, J Bouwman, J Sanders, E Plasmeijer, YS Elshot, RA Scolyer, BA van de Wiel, DS Peeper, ACJ van Akkooi, GV Long, CU BlankFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.